Summary of minutes of EUCAST Steering Committee Meeting
Växjö, Sweden, 8-9 September 2008

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Prof Gunnar Kahlmeter GK Chairperson Sweden
Dr Christian Giske CG SRGA Sweden
Dr Antti Hakanen AH EUCAST Finland
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy CS CA-SFM France
Dr Martin Steinbakk MS NWGA Norway
Prof Paul Tulkens PT EUCAST ISC

1 Chairman’s welcome
GK welcomed Dr Christian Giske as new representative of the SRGA.

2 Minutes of meeting of 12-13 June 2008
The minutes were accepted as a correct record.

3 Matters arising from minutes of 12-13 June 2008
Minocycline MIC data for H. influenzae is being collected.

The next version of the WHOnet program may be able to export data in the EUCAST Excel format.

Quinupristin-dalfopristin MIC distributions are being sought.

There are no current plans to extend the license for moxifloxacin to anaerobic intra-abdominal infections.

Anaerobe MIC distributions have been added to the wild type MIC distributions website.

Dosing of a new cephalosporin is being questioned.

For anaerobes breakpoints were added for some beta-lactam agents and IE for phenoxyethyl penicillin.

A response from the company to proposed EUCAS breakpoints for a new glycopeptide is still awaited.

A reply has been received from the company regarding why MICs for a new cephalosporin for P. vulgaris are significantly higher by broth dilution than by agar dilution.

The revised carbapenem table with doripenem breakpoints will be released soon.

Penicillin breakpoints: Replies are being received to a questionnaire to the General Committee asking for the doses of penicillins commonly used for CAP caused by S. pneumoniae. A table will be produced with different doses and Pk/Pd breakpoints covering the dosage range. In the absence of outcome data for for viridans streptococci isolates with benzylpenicillin MICs 4-8 mg/L it was agreed not to change proposed breakpoints at present. Data supporting amoxicillin breakpoints of 0.25/2 mg/L for meningococci to avoid reporting amoxicillin resistant, ampicillin susceptible are being examined. The penicillin table was revised before release on the website.

The revised carbenemem table with doripenem breakpoints will be released soon.

Penicillin breakpoints: Replies are being received to a questionnaire to the General Committee asking for the doses of penicillins commonly used for CAP caused by S. pneumoniae. A table will be produced with different doses and Pk/Pd breakpoints covering the dosage range. In the absence of outcome data for for viridans streptococci isolates with benzylpenicillin MICs 4-8 mg/L it was agreed not to change proposed breakpoints at present. Data supporting amoxicillin breakpoints of 0.25/2 mg/L for meningococci to avoid reporting amoxicillin resistant, ampicillin susceptible are being examined. The penicillin table was revised before release on the website.

A separate breakpoint column has been added for streptococci other than Groups A, B, C, G and S. pneumoniae. Some gaps in breakpoints will need to be filled.
Some MIC distributions for *Clostridium difficile* have been received but more would be welcome.

No MIC distributions for *H. pylori* have yet been received from expert groups.

Data regarding colistin breakpoints for *Pseudomonas* spp. are being sought.

**4 New drugs**

Company reponses to proposed EUCAST breakpoints for a new quinolone were discussed.

There has been no response from the company to proposed EUCAST breakpoints for a new glycopeptide.

The application for licensing of dalbavancin has been withdrawn by Pfizer.

A formal presentation to EUCAST of a new glycopeptide has been scheduled for November 2008.

A formal presentation to EUCAST of a new diaminopyrimidine agent has been scheduled for November 2008.

The licensing process for a new cephalosporin is in progress.

**5 Status of EUCAST documents**

The current status of documents was reviewed.

**6 Expert rules subcommittee**

The intention is to publish the supplement in CMI early in 2009. It was agreed that the rules should be updated in time for publication in the supplement. A computer program for application of the rules is being developed. Methods of detection of specific resistance mechanisms will not be included with expert rules.

**7 Antifungal susceptibility testing subcommittee**

Discussions are underway regarding posaconazole and itraconazole breakpoints.

**8 Anaerobe subcommittee**

No new information.

**9 Mycobacterium subcommittee**

Funding is available for this subcommittee. The exact remit and structure are to be defined.

**10 Request from Aventis for telithromycin rationale document**

The rationale for telithromycin harmonised breakpoints has been requested.

**11 Organisms/agents requiring breakpoints**

There have been few replies from the General Committee regarding whether any EUCAST breakpoints need review and whether there are any other organism-antibiotic combinations that should have breakpoints. The invitation will remain open until the end of the year.

**12 CLSI**

Noted that CLSI may be coming to an arrangement with the FDA over breakpoint setting.

**13 ESCMID**

A EUCAST Postgraduate Educational Workshop is unlikely before 2010. A EUCAST workshop at ECCMID 2009 has been agreed and participants invited. A EUCAST symposium at ECCMID 2009 on implementation of EUCAST breakpoints will be offered to the organisers.

**14 EUCAST disk diffusion method**

A “call for tenders” is expected from ECDC before the end of the year. ESCMID is supporting preliminary work.

**15 ECDC**

has accepted the EUCAST-ESCMID proposal for a European Susceptibility Organisation. Funding will be for 3 years and it is expected that a representative of ECDC will attend Steering Committee meetings.

**16 EMEA**

will give a presentation to the Steering Committee in November on the EMEA regulatory process.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>17</strong></td>
<td><strong>EUCAST MIC tables</strong> MIC breakpoint tables would be provided on the EUCAST website in pdf format so that formatting is maintained. It will be possible to print all tables together.</td>
</tr>
<tr>
<td><strong>18</strong></td>
<td><strong>Oral cephalosporins</strong> Draft breakpoints were reviewed. The draft breakpoints will be discussed again at the next meeting in November and will then be sent out for general consultation.</td>
</tr>
<tr>
<td><strong>19</strong></td>
<td><strong>Revision of carbapenem breakpoints</strong> Evidence for changing breakpoints is not conclusive and breakpoints will not be changed at this time. Draft rationale documents are being updated.</td>
</tr>
<tr>
<td><strong>20</strong></td>
<td><strong>Revision of glycopeptide breakpoints</strong> Proposed revised breakpoints will be sent for consultation with a note on why the changes have been made.</td>
</tr>
<tr>
<td><strong>21</strong></td>
<td><strong>Any other business</strong> Guidance on when additional testing, such as MICs, is appropriate will be produced for the disk diffusion method.</td>
</tr>
</tbody>
</table>
| **22** | **Next meetings**  
6-17 February 2009. Madrid, Spain  
19-20 May 2009. Helsinki, Finland (following ECCMID)  
7-8 September 2009. Leipzig/Munich, Germany  
23-24 November 2009. Nice, France |

Ratified summary of minutes of meeting 8-9 September 2008. Prepared by DB, GK and RC
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Organization</th>
<th>Address</th>
<th>Phone</th>
<th>Mobile</th>
<th>Fax</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Derek F.J. Brown</td>
<td>Scientific Secretary</td>
<td>Health Protection Agency</td>
<td>Clinical Microbiology and Public Health Laboratory Addenbrooke's Hospital, Hills Road Cambridge CB2 0QW United Kingdom</td>
<td>+44 1223 257020</td>
<td>+44 7762 746692</td>
<td>+44 1223 242775</td>
<td><a href="mailto:dfjb2@cam.ac.uk">dfjb2@cam.ac.uk</a></td>
</tr>
<tr>
<td>Dr. Rafael Cantón</td>
<td>Clinical Data Co-ordinator.</td>
<td>Servicio de Microbiología Hospital Universitario Ramón y Cajal Carretera de Colmenar Km 9,1 28034-Madrid Spain</td>
<td>Tel: + 34 913 368 330 Mobile: + 34 619 235 954 Fax: + 34 913 368 809 Email: <a href="mailto:rcanton.hrc@salud.madrid.org">rcanton.hrc@salud.madrid.org</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Luc Dubreuil</td>
<td>Chairperson</td>
<td>Clinical Bacteriology Department, Faculté de Pharmacie, BP83, 59006 Lille CEDEX, France</td>
<td>Tel: + 358 2 331 6600 Mobile: +358 40 531 6953 Fax: +358 2 331 6699 Email: <a href="mailto:luc.dubreuil@univ-lille2.fr">luc.dubreuil@univ-lille2.fr</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Antti Hakanen</td>
<td>Chairperson</td>
<td>National Public Health Institute</td>
<td>Klinik mikrobiologi Centrallassaretet 351 85 Växjö Sweden</td>
<td>+46 470587477 Mobile: +46 709844685 Fax: +46 470587455 Email: <a href="mailto:gunnar.kahlmeter@ltkronoberg.se">gunnar.kahlmeter@ltkronoberg.se</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Gunnar Kahlmeter</td>
<td>Chairperson</td>
<td>Klinisk mikrobiologi Centrallassaretet 351 85 Växjö Sweden</td>
<td>Tel: + 44 117 959 5651 Mobile: +44 7919 337856 Fax: +44 117 959 3154 Email: <a href="mailto:alasdair.maccgowan@north-bristol.swehs.nhs.uk">alasdair.maccgowan@north-bristol.swehs.nhs.uk</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Johan W. Mouton,</td>
<td>Chairperson</td>
<td>Dept Medical Microbiology and Infectious Diseases</td>
<td>Nijmegen The Netherlands</td>
<td>+31 24 3657514 Mobile: +31 651381270 Fax: +31 24 3657516 Email: <a href="mailto:mouton@cwz.nl">mouton@cwz.nl</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Christian Giske,</td>
<td>Chairperson</td>
<td>Department of clinical microbiology L2:02</td>
<td>Karolinska University Hospital, Solna SE-17176 Stockholm Sweden</td>
<td>+46 8 517 73574 Mobile: +46 Fax: +46 8 30 80 99 Email: <a href="mailto:christian.giske@karolinska.se">christian.giske@karolinska.se</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof Claude-James Soussy</td>
<td>Chairperson</td>
<td>Hôpital Henri Mondor Service de Bactériologie</td>
<td>51 Av De Lattre De Tassigny Créteil 94010 France</td>
<td>+33 149812831 Mobile: Fax: Email: <a href="mailto:claude-james.soussy@hmn.ap-hop-paris.fr">claude-james.soussy@hmn.ap-hop-paris.fr</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Arne C. Rodloff</td>
<td>Chairperson</td>
<td>Inst fur Medizinische Mikrobio der Universität Leipzig Liebigstr 24 Leipzig 04103 Germany</td>
<td>Tel: +49 3419715200 Mobile: +49 175 365 6650 Fax: +49 3419715209 Email: <a href="mailto:acr@medizin.uni-leipzig.de">acr@medizin.uni-leipzig.de</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Martin Steinbakk</td>
<td>Chairperson</td>
<td>Department of Microbiology</td>
<td>Akershus University Hospital P.O. Box 23 N-1478 Lørenskog Norway</td>
<td>+47 67 928 500 Mobile: +47 913 97667 Fax: +47 67 928 519 Email: <a href="mailto:martin.steinbakk@ahus.no">martin.steinbakk@ahus.no</a> Email: <a href="mailto:drmartin@online.no">drmartin@online.no</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professor Paul M. Tulkens</td>
<td>Chairperson</td>
<td>Unité de Pharmacologie</td>
<td>Université Catholique de Louvein UCL 7370 avenue E. MOUNIER B-1200 Bruxelles Belgium</td>
<td>Tel: +32 2 762 21 36 or 764 73 71 Mobile: Fax: +32 2 764 73 73 Email: <a href="mailto:tulkens@farcn.ucl.ac.be">tulkens@farcn.ucl.ac.be</a></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>